Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-21. (Canceled).

Claim 22. (Currently Amended): A recombinant soluble T cell receptor (TCR) which comprises:

i) a TCR α ~~or γ~~ chain extracellular domain which comprises a variable domain and a constant domain, and which has ~~having~~ a first C-terminal ~~dimerisation~~ dimerization peptide which is heterologous to the α ~~or γ~~ chain; and

ii) a TCR β ~~or δ~~ chain extracellular domain which comprises a variable domain and a constant domain, and which has ~~having~~ a second C-terminal ~~dimerisation~~ dimerization peptide which is heterologous to the β ~~or δ~~ chain;

wherein the first ~~dimerisation~~ dimerization ~~domain~~ peptide and the second ~~dimerisation~~ dimerization ~~domain~~ peptide are specifically ~~heterodimerised~~ heterodimerized to form a ~~heterodimerisation~~ heterodimerization domain; ~~and~~

wherein a ~~disulphide~~ disulfide bond present in native TCRs between the α and β ~~or γ and δ chain~~ chains is absent; and

wherein the TCR is capable of specific binding to a peptide-MHC complex at a concentration of at least 40 µg/ml.

Claims 23-24. (Canceled).

Claim 25. (Previously Presented): A recombinant TCR according to claim 22 wherein said TCR is stable at a concentration below 1 mg/ml.

Claim 26. (Previously Presented): A recombinant TCR according to claim 22 wherein said TCR is stable at a concentration of about 10 μg/ml.

Claim 27. (Currently Amended): The recombinant TCR according to claim 22 wherein the ~~heterodimerisation~~ heterodimerization domain is a coiled coil domain.

Claim 28. (Currently Amended): The recombinant TCR according to claim 27 wherein the ~~dimerisation~~ dimerization peptides are c-jun and c-fos ~~dimerisation~~ dimerization peptides.

Claim 29. (Currently Amended): The recombinant TCR according to claim 22, comprising a flexible linker located between the TCR chains and the ~~dimerisation~~ dimerization peptides.

Claim 30. (Previously Presented): The recombinant TCR according to claim 22, expressed in an *E. coli* expression system.

Claim 31. (Previously Presented): The recombinant TCR according to claim 22, which is biotinylated at the C-terminus.

Claim 32. (Previously Presented): The recombinant TCR according to claim 22, labeled with a detectable label.

Claim 33. (Previously Presented): The recombinant TCR according to claim 22, linked to a therapeutic agent.

Claim 34. (Currently Amended): A recombinant non-membrane-bound T cell receptor produced by:

i) expressing a TCR α ~~or~~ γ chain extracellular domain which comprises a variable domain and a constant domain, and which has ~~having~~ a first C-terminal ~~dimerisation~~ dimerization peptide which is heterologous to the α ~~or~~ γ chain;

ii) expressing a TCR β ~~or~~ δ chain extracellular domain which comprises a variable domain and a constant domain, and which has ~~having~~ a second C-terminal ~~dimerisation~~ dimerization peptide which is heterologous to the β ~~or~~ δ chain; and

iii) refolding the chains together *in vitro* to produce a TCR heterodimer;

wherein the first and second ~~dimerisation~~ dimerization peptides form a ~~heterodimerisation~~ heterodimerization domain; ~~and~~

wherein a ~~disulphide~~ disulfide bond present in native TCRs between the α and β ~~or~~ γ ~~and~~ δ ~~chain~~ chains is not formed; and

wherein the TCR is capable of specific binding to a peptide-MHC complex at a concentration of at least 40 μg/ml.

Claim 35. (New): The recombinant TCR according to claim 33, wherein the therapeutic agent is an immunostimulatory agent.